sodium stibogluconate
Sponsors
Drugs for Neglected Diseases, The Cleveland Clinic, Case Comprehensive Cancer Center, M.D. Anderson Cancer Center, Waisenmedizin e. V. Promoting Access to Essential Medicine
Conditions
Acute Myeloid LeukemiaAdvanced CancerCancerCutaneous LeishmaniasisMyelodysplastic SyndromesMyeloid MalignancyP53 MutationPrimary Visceral Leishmaniasis
Phase 1
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
TerminatedNCT00311558
Start: 2005-10-31End: 2012-01-31Updated: 2018-01-26
Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers
CompletedNCT00498979
Start: 2007-05-31End: 2012-01-31Updated: 2020-07-24
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
CompletedNCT00629200
Start: 2006-09-13End: 2010-02-10Updated: 2018-11-15
Phase I/II Trial of Sodium Stibogluconate in Myelodysplastic Syndrome
TerminatedNCT01009502
Start: 2009-07-31End: 2013-05-31Updated: 2013-11-08
Phase 2
Rationales for Wound Care Management in Old World Cutaneous Leishmaniasis Patients
CompletedNCT00996463
Start: 2010-01-31End: 2011-03-31Target: 63Updated: 2011-03-28
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
CompletedNCT01011309
Start: 2009-10-31End: 2011-12-31Updated: 2013-12-11
Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations
NCT04906031
Start: 2020-06-01End: 2024-02-01Target: 5Updated: 2021-06-09
African leishmaniasis: From clinical research to access
Active, not recruitingPACTR202205775486864
Start: 2022-06-30Target: 326Updated: 2026-01-27
LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study
CompletedNCT05957978
Start: 2024-03-29End: 2025-11-13Updated: 2025-12-18
Phase 3
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
CompletedNCT00255567
Start: 2004-11-30End: 2010-01-31Updated: 2016-03-22
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
CompletedNCT03129646
Start: 2018-01-24End: 2020-12-11Updated: 2024-02-29